培西替康与年龄相关性黄斑变性中不完全视网膜色素上皮和光感受器外萎缩进展的关联:FILLY随机临床试验的事后分析
该事后分析纳入FILLY试验中167例继发于年龄相关性黄斑变性的地图样萎缩患者,比较玻璃体腔注射培西替康每月、隔月与假注射对12个月内不完全视网膜色素上皮和光感受器外萎缩进展为完全萎缩的影响,结果显示培西替康组进展率较低,提示其可能在地图样萎缩发生前更早期发挥作用。
要点
- 培西替康每月组12个月进展率50.0%(9/18),假注射组81.8%(27/33),P=.02。
- 培西替康隔月组进展率60.6%(20/33),假注射组81.8%(27/33),P=.06。
- 培西替康每月组相对危险度0.61(95%CI 0.37-1.00),隔月组0.74(95%CI 0.54-1.02)。
核心结论
- 接受玻璃体腔培西替康注射的眼内不完全视网膜色素上皮和光感受器外萎缩进展为完全萎缩的比率低于对照组,提示培西替康可能在地图样萎缩发生前的更早期阶段发挥作用。
研究设计与样本
- FILLY试验是一项2期多中心、随机、单盲、假注射对照试验,评估玻璃体腔注射培西替康治疗12个月的效果。
- 本分析为事后分析,纳入167例继发于年龄相关性黄斑变性的地图样萎缩患者,每月组41例、隔月组56例、假注射组70例,均完成12个月访视且未发生渗出性年龄相关性黄斑变性。
- 干预为玻璃体腔注射培西替康15 mg或假注射,每月或隔月一次,持续12个月。
- 主要结局为基线至6个月和12个月时不完全视网膜色素上皮和光感受器外萎缩进展为完全视网膜色素上皮和光感受器外萎缩。
主要发现
- 基线时不完全萎缩在每月组为45.0%(18/40)、隔月组为61.8%(34/55)、假注射组为50.7%(34/67)。
- 12个月时进展为完全萎缩在每月组为50.0%(9/18,P=.02 vs 假注射)、隔月组为60.6%(20/33,P=.06 vs 假注射)、假注射组为81.8%(27/33)。
- 与假注射相比,12个月进展的相对危险度在每月组为0.61(95%CI 0.37-1.00),隔月组为0.74(95%CI 0.54-1.02)。
关键数值与推荐
- 不完全萎缩和完全萎缩的判定依据萎缩分类会议标准,由 masked readers 分析距离地图样萎缩边界500 μm以外区域的光谱域光学相干断层扫描。
临床怎么用
- 原文结论提示培西替康可能在地图样萎缩发生前的更早期阶段发挥作用,但未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Change in areas of incomplete retinal pigment epithelium (RPE) and outer retinal atrophy (iRORA) within eyes with geographic atrophy (GA) might reflect similar changes among eyes with drusen but no GA. OBJECTIVE: To evaluate the potential association of pegcetacoplan with progression of iRORA in eyes with GA secondary to AMD. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of the phase 2 multicenter, randomized, single-masked, sham-controlled FILLY trial of intravitreal pegcetacoplan for 12 months took place from February 2 to July 7, 2020. Participants comprised 167 patients with GA secondary to AMD who received pegcetacoplan monthly (n = 41) or every other month (n = 56) or a sham injection (n = 70) in the FILLY trial, completed the month 12 study visit, and did not develop exudative AMD. INTERVENTIONS: Intravitreal pegcetacoplan, 15 mg, or sham injection, monthly or every other month for 12 months. MAIN OUTCOMES AND MEASURES: Masked readers analyzed spectral-domain optical coherence tomography scans in regions beyond a perimeter of 500 μm from the GA border according to the Classification of Atrophy Meetings criteria. Primary outcome measures were progression from iRORA to complete RPE and outer retina atrophy (cRORA) from baseline to 6 and 12 months. RESULTS: Among the 167 patients in the study, at baseline, iRORA was present in 45.0% of study eyes (18 of 40) in the pegcetacoplan monthly group, 61.8% of study eyes (34 of 55) in the pegcetacoplan every other month group, and 50.7% of study eyes (34 of 67) in the sham group. At 12 months, progression from iRORA to cRORA occurred in 50.0% of study eyes (9 of 18) in the pegcetacoplan monthly group (P = .02 vs sham), 60.6% of study eyes (20 of 33) in the pegcetacoplan every other month group (P = .06 vs sham), and 81.8% of study eyes (27 of 33) in the sham group. Compared with sham treatment, the relative risk of progression at 12 months from iRORA to cRORA was 0.61 (95% CI, 0.37-1.00) for eyes in the pegcetacoplan monthly group and 0.74 (95% CI, 0.54-1.02) for eyes in the pegcetacoplan every other month group. CONCLUSIONS AND RELEVANCE: Eyes receiving intravitreal pegcetacoplan had lower rates of progression from iRORA to cRORA compared with controls, suggesting a potential role for pegcetacoplan therapy earlier in the progression of AMD prior to the development of GA. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02503332.
引用
- Nittala MG, Metlapally R, Ip M, et al. Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial. JAMA Ophthalmol. 2022. PMID: 35113137. doi:10.1001/jamaophthalmol.2021.6067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。